

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US <b>101524359</b>
		SERIAL NO.	Unassigned
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Benoit Chabot et al.
		FILING DATE	Herewirth
		GROUP	Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CA	Skordis, L, etal, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, 2003, PNAS, Vol 100, No. 7, Pgs. 4114-4119.
	CB	Cartegni, L, etal, Correction of disease-associated exon skipping by synthetic exon-specific activators, 2003, Nat. Struct. Bio., Vol 10, No.2, Pgs. 120-125.
	CC	Shirohzu, H., etal, Repression of Aberrant Splicing in Human β-Globin Pre-mRNA With Hbe Mutation by Antisense Oligoribonucleotide or Splicing Factor SF2/ASF, 2000, Intl Jour. of Hemat., Pgs. 28-33.
	CD	Taylor, J, etal, Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides, 1999, Abstract-Nature Biotech. -XP-002262732-Pgs.1097-1100.
	CE	Lacerra G, etal, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, 2000, Abstract-PNAS-XP00226733-Pgs. 9591-9596.
	CF	Chabot,B.,etal, An Intron Element Modulating 5' Splice Site Selection in the hnRNP A1 Pre-mRNA Interacts with hnRNP A1, 1997, Molecular & Cell. Bio-Amer Soc. For Micro., Pgs. 1776-1786.
/DS/	CG	Burd,C,etal, RNA binding specificity of hnRNP A1:significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing, 1994, EMBO Jour., Pgs. 1197-1204.
EXAMINER: /Dana Shin/		DATE CONSIDERED: 01/25/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) <b>SUPPLEMENTAL</b>		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CE	Lacerra G, et al, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, 2000, <u>FULL ARTICLE</u> , Pgs. 9591-9596. <u>(Note: On IDS filed 2-14-05 we included an ABSTRACT ONLY for this article)</u>
	CH	VILLEMAIRE et al., Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J. Biol. Chem., Vol. 278, No. 5050031-50039 (2003).
	CI	NASIM et al., High-affinity hnRNP AI binding sites and duplex-forming inverted repeats have similar effects on 5' splice site selection in support of a common looping out and repression mechanism, RNA, Vol. 8:1078-1 079 (2002)
	CJ	GOYENVALLE et al., Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, Vol. 306:1796-1 799 (2004).
	CK	DOMINSKY et al., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 90:8673-8677 (1993).
	CL	SIERAKOWSKA et al., Repair of thalassemic human R-globin mRNA in mammalian cells by antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, Vol. 93:12840-12844 (1996).
/DS/	CM	FRIEDMAN et al., Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J. Biol. Chem., Vol. 274, No. 51:36193-36199 (1999).

EXAMINER:	/Dana Shin/	DATE CONSIDERED:	01/25/2008
-----------	-------------	------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;  
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CN	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No.13:2415-2423 (1999).
	CO	SIERAKOWSKA et al., Sensitivity of splice sites to antisense oligonucleotides in vivo, RNA, Vol. 5:369-377 (1999).
	CP	KARRAS et al., Peptide nucleic acids are potent modulators of endogenous Pre-mRNA splicing of the murine Interleukin receptor-α chain, Biochem., Vol. 40:7853-7859 (2001).
	CQ	SAZANI et al., Nuclear antisense effects of neutral, anionic and cationic and cationic oligonucleotide analogs, Nucl. Acid Res., Vol. 29, No. 19:3965-3974 (2001).
	CR	DOMINSKY et al., Identification and characterization by antisense oligonucleotides of exon and intron CM sequences required for splicing, Mol. and Cell. Biol., Vol. 14, No. 11:7445-7454 (1994).
	CS	MERCATANTE et al., Modification of alternative splicing pathways as a potential approach to chemotherapy, Pharmac. and Therap., Vol. 85:237-243 (2000).
/DS/	CT	WILTON et al., Specific removal of the non-sense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromusc. Dis., Vol. 9:330-338 (1999).

EXAMINER: /Dana Shin/

DATE CONSIDERED: 01/25/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;  
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO.	2891-1-001PCT/US
		SERIAL NO.	10/524,359
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT	Benoit Chabot et al.
		FILING DATE	February 14, 2005
		GROUP	Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB-CLASS	TRANSLATION YES NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/DS/	CU	GORMAN et al., Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc. Nati. Acad. Sci. USA, Vol. 95:4929-4934 (1998).
	CV	SUTER et al., Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations, Hum. Mol. Gen., Vol. 8, No. 13:2415-2423 (1999).
	CW	SAZANI et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nature Biotech., Vol. 20: 1228-1 233 (2002).
	CX	SAZANI et al., Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing, J. Clin. Invest., Vol. 112, No. 4:481-486 (2003).
	CY	MERCATANTE et al., Modification of alternative splicing of bcl-x pre-mRNA in prostate and breast cancer cells, J. Biol. Chem., Vol. 276, No. 19:16411-16417 (2001).
/DS/	CZ	MERCATANTE et al., Cellular response to an antisense-mediated shift of bcl-x pre-mRNA splicing and antineoplastic agents, J. Biol. Chem., Vol. 277, No. 51:49374-49382 (2002).

EXAMINER: /Dana Shin/

DATE CONSIDERED: 01/25/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;  
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.